Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncogene. 2006 Mar 13;25(11):1620-8.

Cyclin D1: polymorphism, aberrant splicing and cancer risk.

Author information

  • 1Department of Cell Biology, University of Cincinnati, Cincinnati, OH 45267, USA. erik.knudsen@uc.edu

Abstract

The cyclin D1 proto-oncogene exercises powerful control over the mechanisms that regulate the mitotic cell cycle, and excessive cyclin D1 expression and/or activity is common in human cancers. Although somatic mutations of the cyclin D1 locus are rarely observed, mounting evidence demonstrates that a specific polymorphism of cyclin D1 (G/A870) and a protein product of a potentially related alternate splicing event (cyclin D1b) may influence cancer risk and outcome. Herein, we review the epidemiological and functional literatures that link these alterations of cyclin D1 to human tumor development and progression.

PMID:
16550162
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk